Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been given a $13.00 target price by investment analysts at Cantor Fitzgerald in a report issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 145.28% from the company’s previous close.

A number of other research firms also recently weighed in on AXSM. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 11th. Brean Capital began coverage on shares of Axsome Therapeutics in a report on Monday, October 3rd. They issued a “buy” rating and a $20.00 target price on the stock.

Shares of Axsome Therapeutics (NASDAQ:AXSM) remained flat at $5.45 during trading on Wednesday. 21,129 shares of the company traded hands. The firm’s market capitalization is $104.38 million. The company has a 50 day moving average of $6.63 and a 200-day moving average of $7.27. Axsome Therapeutics has a one year low of $5.25 and a one year high of $13.71.

COPYRIGHT VIOLATION NOTICE: “Axsome Therapeutics, Inc. (AXSM) PT Set at $13.00 by Cantor Fitzgerald” was originally published by Watch List News and is the propert of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this piece of content can be read at http://www.watchlistnews.com/axsome-therapeutics-inc-axsm-pt-set-at-13-00-by-cantor-fitzgerald/1060079.html.

A number of institutional investors have recently modified their holdings of AXSM. Citadel Advisors LLC purchased a new position in shares of Axsome Therapeutics during the third quarter valued at approximately $104,000. Baldwin Brothers Inc. MA purchased a new position in shares of Axsome Therapeutics during the third quarter valued at approximately $119,000. Teachers Advisors Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $128,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $134,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $161,000. Institutional investors own 32.94% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

5 Day Chart for NASDAQ:AXSM

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.